# OBJECTIVE CELL PARAMETERS IN PROSTATIC CARCINOMA

> **NIH NIH R01** · MONTEFIORE MEDICAL CENTER (BRONX, NY) · 1987 · $116,106

## Abstract

We propose to define in cells of prostatic carcinoma objective quantitative
parameters of diagnostic and prognostic value measured by flow cytometry
and image analysis.  We will study cells, or nuclei derived therefrom, in
approximately 300 patients with prostatic carcinoma and approximately 75
randomized patients with benign prostatic disease.  The cell samples will
be obtained primarily by thin needle aspiration biopsy, or, if necessary,
from surgically removed tissues.

By flow cytometry we will establish the distribution of DNA in populations
of cells from cancer and benign hyperplasia.  Normal prostates from
autopsies will serve as controls.  In representative cases the DNA
determinations on Feulgen stained cells in smears by cytophotometry will be
compared with flow cytometry.  Our high resolution computer-based taxonomic
image analysis system will select cell descriptors of value in
distinguishing benign from malignant prostatic cells in smears.  Further
differences among subgroups of prostatic cancer cells of divergent
diagnostic and prognostic value will be sought.  The system also provides
objective quantitation of morphologic features of cells and cell components
such as cell size, nuclear size and shape, and nucleocytoplasmic ratio,
etc. that has been shown capable of identifying subpopulation of seemingly
similar cells.

The data thus obtained will be correlated by statistical analysis with each
other and with several parameters commonly used to evaluate patients with
prostatic cancer:  histologic grading (after Gleason), clinical staging and
follow-up.

While it is known that histologic grading and clinical staging provide a
fair statistical assessment of prognosis, the striking differences in
behavior observed among individual patients with various grades of
prostatic cancer strongly suggest that these 2 parameters have only general
clinical value.  Preliminary evidence outlined in this application suggests
that the proposed research may lead to a more accurate assessment of
behavior of prostate cancer in individual patients and thus to a better
choice of therapeutic options.

## Key facts

- **NIH application ID:** 3172616
- **Project number:** 5R01CA034790-04
- **Recipient organization:** MONTEFIORE MEDICAL CENTER (BRONX, NY)
- **SAM.gov UEI:** FP1VD1HU5HV7
- **Principal Investigator:** LEOPOLD G. KOSS
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1987
- **Award amount:** $116,106
- **Award type:** 5
- **Project period:** 1984-07-01 → 1989-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3172616

## Citation

> US National Institutes of Health, RePORTER application 3172616, OBJECTIVE CELL PARAMETERS IN PROSTATIC CARCINOMA (5R01CA034790-04). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3172616. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*